Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 11

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
 (CMC) 
     406  
     339  
     67  
     19.8%
  
    Subtotal 
     1,319  
     1,959  
     (640) 
     (32.7)%
  
    Research and development expenses 
     2,165  
     3,294  
     (1,129) 
     (34.3)%
  
    General and administrative expenses 
     1,980  
     1,717  
     263  
     15.3%
  
    Total operating expenses 
     4,145  
     5,011  
     (866) 
     (17.3)%
  
    Loss from operations 
    $(4,145) 
    $(5,011) 
    $(866) 
     (17.3)%

Note 6. Other Accrued Liabilities

Other accrued liabilities at March 31, 2025 and December
31, 2024 include the following:

 Schedule of Other Accrued Liabilities

    March 31,  2025  
    December 31, 2024 
  
    Amounts due to contract research organizations and other contractual agreements 
    $952,003  
    $1,048,036 
  
    Accrued payroll and related benefits 
     2,550,804  
     1,945,111 
  
    Accrued professional fees and other 
     40,600  
     40,600 
  
    Total 
    $3,543,407  
    $3,033,747 

    10

Note 7. Stockholders’ Equity

On May 15, 2024, the Company filed with the SEC a
shelf registration statement on Form S-3 (the “2024 Registration Statement”) for the offer and sale of up to $75 million of
its securities. The 2024 Registration Statement was declared effective on May 22, 2024. The 2024 Registration Statement is intended to
provide the Company with flexibility to raise capital in the future for general corporate purposes. However, the Company’s ability
to offer and sell its securities in a primary offering on the 2024 Registration Statement is limited by General Instruction I.B.6 of Form
S-3 (the “Baby Shelf Limitation